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Fragment-based drug design has introduced a bottom-up process for drug development, with
improved sampling of chemical space and increased effectiveness in early drug discovery.
Here, we combine the use of pharmacophores, the most general concept of representing
drug-target interactions with the theory of protein hotspots, to develop a design protocol for
fragment libraries. The SpotXplorer approach compiles small fragment libraries that max-
imize the coverage of experimentally confirmed binding pharmacophores at the most pre-
ferred hotspots. The efficiency of this approach is demonstrated with a pilot library of 96
fragment-sized compounds (SpotXplorer0) that is validated on popular target classes and
emerging drug targets. Biochemical screening against a set of GPCRs and proteases retrieves
compounds containing an average of 70% of known pharmacophores for these targets. More
importantly, SpotXplorer0 screening identifies confirmed hits against recently established
challenging targets such as the histone methyltransferase SETD2, the main protease
(3CLPro) and the NSP3 macrodomain of SARS-CoV-2.
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Fragment-based drug discovery (FBDD) is a lead generationstrategy based on the screening of small polar compoundsthat typically exhibit low affinity towards protein targets.
Previous binding thermodynamics studies revealed that frag-
ments bind to protein hotspots by choice1–3. Their polar char-
acter prevents apolar desolvation compensation for rigid body
entropy loss4 and generates productive fragment binding. Indeed,
fragments have been shown to bind to protein hotspots by a
limited number of optimal geometry H-bonds5,6. Good overlap
with the structure-based pharmacophores at the primary hotspot
(binding site region with the largest contribution to the ligand
binding free energy) leads to robust binding3. Therefore the
nature and quality of binding interactions is fundamental to the
choice of fragment starting points for drug discovery programs7.
Recent studies have shown that there is still significant con-
troversy on the applicability of the fragment-based approach to
drug discovery3,8. When reviewing fragment starting points,
target specificity was often identified as an issue. An analysis of
the active fragments from 35 campaigns on 20 targets at Novartis
indicated that 63% of the screened fragments had never been
observed as hits9. Instead, the team promoted privileged frag-
ments as high-value library members active on more than one
target. Another analysis found that 20% of fragments in crystal-
lized complexes in the Protein Data Bank (PDB) have multiple
protein targets10. Since there is often an opportunity to build
selectivity while evolving fragments11, features encoded in fre-
quent hitter fragments can productively be considered part of a
representative set of binding pharmacophores. The evolutionarily
conserved nature of binding hotspots12 and the conservation of
pharmacophores found in certain target classes13, suggests that
the number of distinct structure-based pharmacophores should
be limited. Our idea was to identify the set of fragment phar-
macophores that covers the diversity of known hotspots and use
them to design a small, efficient fragment library to recognize this
diversity.
In the present work, we analyze critical interactions found at
the hotspot of target proteins to derive fragment pharmacophores
represented in fragment-protein complexes available in the PDB.
Using this information, we design a minimal diverse set of
commercial fragments (the SpotXplorer0 library) covering the
majority of the experimental binding pharmacophores to be used
for the identification of fragment starting points for drug dis-
covery targets. After validating this library against established
target classes and reproducing a majority of the known binding
pharmacophores, we address more challenging targets. Besides
covering a high percentage of known pharmacophores of well-
established drug targets, our approach identified the first non-
nucleoside type inhibitor for the histone methyltransferase SET
domain containing 2 (SETD2), an emerging leukemia target14.
Furthermore, we present promising starting points for two recent
COVID-19 targets, the 3CL main protease and the NSP3 mac-
rodomain of SARS-CoV-2.
Results
Experimental fragment-binding modes are represented by a
limited set of pharmacophores. Experimental fragment phar-
macophores were extracted from the available protein-fragment
structures in the Protein Data Bank. More than 3300 PDB entries
with fragment-sized ligands, containing 10–16 heavy atoms15,
were filtered and analyzed in a stepwise workflow reported in
Fig. 1 and, in more detail, in the Supplementary Information,
section 1. The FTMap approach (ATLAS software)16 was utilized
to identify fragment-sized ligands in a binding hotspot of the
target protein16,17. FTMap is an established protein mapping
algorithm that predicts the location and strength of hotspots
within a protein. The method distributes small organic probe
molecules of varying size, shape, and polarity on a dense grid
defined on the protein surface, finds the most favorable positions
for each probe type, and performs local energy minimization
allowing for probe flexibility. Then, it clusters the probes and
ranks the clusters on the basis of their average energy. Regions
that bind multiple probe clusters are defined as the predicted
binding hotspots. (The method is described in more detail in the
Supplementary Information, section 1.3.) Schrödinger’s ePhar-
macophore module was then employed to extract a pharmaco-
phore model for each protein–ligand complex. A maximum of
four available features having the largest energetic contributions
to protein–ligand binding18,19 were extracted for each ligand.
In many cases, more than one protein-fragment complex was
available for a single protein target, often with similar binding
modes and pharmacophores. Moreover, binding pharmacophores
were often conserved even at the fragment level among groups of
similar or related proteins, with the kinase hinge binding motif
being one of the most well-known examples20. Consequently,
many of the 3584 extracted pharmacophore models were
redundant or very similar, supporting our expectation that the
number of distinct binding pharmacophores was relatively small.
Therefore, we applied a two-step clustering process to identify a
non-redundant set of pharmacophores. First, pharmacophores
containing the exact same set of features were grouped together
into 141 level 1 clusters, e.g., all pharmacophores that contain an
H-bond donor (D) and two aromatic ring (R) features belong to
the DRR group (one letter for each feature in alphabetical order).
Second, members of each such group were spatially aligned to
each other and a pairwise root-mean-squared distance (RMSD)
matrix was calculated and processed by a hierarchical clustering
(HCA) algorithm with the complete linkage rule and an RMSD
cutoff of 2 Å. The resulting clusters were labeled with sequential
numbers (e.g., DRR_0, DRR_1, etc.) that denote a specific 3D
arrangement of the features. In total, hotspot-binding fragments
of the sampled fragment-protein complexes contain 425 non-
redundant binding pharmacophores (the top 20 most populated
pharmacophores are included in Supplementary Fig. 2). Even a
small fragment library featuring all 425 pharmacophores could
thus enable fragment hit discovery against a wide range of protein
targets.
Optimizing a small fragment library for pharmacophore cov-
erage and diversity. A first generation fragment library was
designed to cover most of the base set of binding pharmacophores
identified from protein-fragment X-ray structures. By definition,
fragments have small sizes and a limited number of pharmaco-
phore features21 that form only a few characteristic interactions
with their targets5. Therefore, we focused our optimization on the
identification of a minimal set of fragments covering the largest
possible fraction of experimentally validated 2-point and 3-point
binding pharmacophores. Fragment collections from BioBlocks
and other commercially available sources were filtered for size,
rotatable bond count, and other properties (Supplementary
Information, section 2.1), and the absence of known problematic
features22, and matched to the 425 non-redundant pharmaco-
phore models. An important post-processing step was the
detection of submodels. Essentially, if a smaller pharmacophore is
present as a spatially matching subset of a larger pharmacophore
(Fig. 1b), then the molecule is considered as a match for only the
larger one. This way, smaller pharmacophores are represented on
their own right, rather than trivially being present in molecules
with a matching larger pharmacophore (see Fig. 1c, and for more
detail, see section 1.5 of the Supplementary Information). We
stored the results in a 425-bit pharmacophore fingerprint in two
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formats, one with all pharmacophores present and a second with
submodels absent.
With the post-processed pharmacophore information in hand,
we applied a custom-made optimization algorithm for compiling
96 fragment-sized molecules from the filtered vendor datasets.
First, 96 molecules were selected by the MaxMin algorithm23,
based on the distances of their pharmacophore fingerprints. Next,
we defined an objective function as the sum of the diversity of the
selected molecules, the diversity of the pharmacophores (Fig. 1c,
red columns and green rows, respectively), and the overall
coverage of the pharmacophores (ratio of pharmacophores with
at least one matching molecule). Then, members of the selected
fragment set were swapped with other molecules, as long as the
swap increased the objective function of the algorithm. For the
last 10% of compounds, acceptable candidate structures did not
significantly alter the overall diversity, so candidates were chosen
to fill missing or underrepresented pharmacophores.
Compound purchase from five different vendors yielded the
physical SpotXplorer pilot library (SpotXplorer0), containing 96
compounds with a coverage of 76% of the 2-point and 94% of the
3-point, non-redundant binding pharmacophores (Fig. 1d). The
library displays a high degree of structural and pharmacophore
diversity as calculated from chemical (Chem) and pharmaco-
phore (Phph) fingerprints, respectively. Compared to the
collections of the top five most popular commercial fragment
vendors identified on the Practical Fragments blog24, Spot-
Xplorer0 has a significantly higher percentage of compounds that
represent unique 2-point and 3-point binding pharmacophores
(Supporting Information, section 3).
SpotXplorer screening yields selective fragment hits for GPCRs
and proteases. The SpotXplorer0 pilot library was first tested in a
biochemical screening against the representatives of two popular
target classes, G-protein coupled receptors (GPCRs) and pro-
teases. The GPCRs were represented by serotonin (5-HT)
receptors, which control key functions in the central and per-
ipheral nervous systems25. SpotXplorer0 was tested against three
5-HT receptors: 5-HT1A, 5-HT6, and 5-HT7, in a cell-based
radioligand binding assay format. Additionally, SpotXplorer0 was
tested on the serine proteases Factor Xa and thrombin, which are
important molecular targets for anti-coagulant drugs26,27, using
chromogenic protease assays.
Experimental screening successfully identified multiple diverse
fragment hits from the SpotXplorer0 library for each of the
protein targets (Fig. 2a). Remarkably, there is limited overlap
between the hits for the different protein targets. The only
exception was the 5-HT7 receptor, known to have similar
pharmacophores to 5-HT628. Additionally, the main point of
this investigation was to provide a retrospective validation of our
library design approach, and more specifically to determine what
percentage of the known pharmacophores (represented by
previously reported fragment-sized ligands) of a certain protein
target was covered by the fragment hits identified by screening
the optimized SpotXplorer0 library against the same target.
Protein-ligand X-ray structures (PDB)
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Fragment?
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entries, 5795 chains) 
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Fig. 1 SpotXplorer workflow. a Computational workflow for assembling the non-redundant set of fragment binding pharmacophores. Fragment-sized15
ligands from the Protein Data Bank (PDB) were subjected to large-scale FTMap16, 17 analysis to identify hotspot binding fragments. Pharmacophore
features (A—H-bond acceptor, D—H-bond donor, H—hydrophobic group, N—negative charge, P—positive charge, R—aromatic ring, see Supplementary
Information, section 1.7 for more detail) with the largest contributions to the overall free energy of binding were clustered based on their respective feature
sets and binned by paired root-mean-square deviation (RMSD) values (e.g., DRR_0, with 0 being an arbitrarily assigned identifier). b Pharmacophore
models overlaid onto the co-crystallized representative ligand of the cluster. For each fragment fingerprint generated, fit to a larger model necessarily
includes smaller models. Here, DR_0 can be fitted onto the corresponding features of DRR_0; the former is a submodel of the latter. c Compound selection
algorithm. Iterative minimization of both the mean pairwise fingerprint similarity (green rows) and pharmacophore similarity (red columns) with
submodels set to zero and simultaneous maximization of the total number of represented pharmacophores generated the SpotXplorer0 pilot library (96
compounds). d Final coverage and distribution data of the 96-compound set selected using 2-point and 3-point pharmacophores (along with the total
numbers of non-redundant 2-point and 3-point pharmacophores). Pharmacophore (Phph) and chemical (Chem) diversity is measured as mean Tanimoto
similarities59.
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To estimate the mapping efficiency of the SpotXplorer0 library
on the binding hotspots of the individual protein targets, we
analyzed the respective sets of reported fragment-sized ligands in
the ChEMBL database, considering those fragments with at least
millimolar activity expressed as IC50, EC50, Ki or Kd29. The
respective fragment sets were downloaded, prepared and analyzed
with the same workflow that we developed for assembling the
SpotXplorer0 library itself (Supplementary information, section
2.1). Then, the list of matching pharmacophores was collected for
each fragment; combining these lists for the fragment-sized
ligands of a protein target defines the binding pharmacophores
utilized by the given target. The analogous pharmacophore lists
retrieved by SpotXplorer0 hits were cross-checked against those
of the ChEMBL fragment sets to define, what percentage of the
known binding pharmacophores of a given target is covered by
the respective fragment hits from our library.
Remarkably, while there were up to 11 times more fragments
reported in ChEMBL (Table 1), the limited number of fragment
hits from SpotXplorer0 matched the majority of binding
pharmacophores present in the ChEMBL sets (most remarkably
for 5-HT6, where all 2-point and 87.5% of 3-point pharmaco-
phores were retrieved). Figure 2b provides a visual comparison of
the respective pharmacophore sets with black bars corresponding
to pharmacophores, that are represented by at least one fragment
in the respective ChEMBL sets or SpotXplorer0 hit lists. We can
therefore conclude that the minimal set of fragments collected to
SpotXplorer0 retrieved most of the binding pharmacophores
known from the literature.
In addition to pharmacophore coverage, we compared some
basic topological features of the SpotXplorer0 hits vs. ChEMBL
fragments (Fig. 3). Information about the hydrogen bonding
patterns and general ring types of each pattern is embedded in the
pharmacophores. Although there is a wide range of ring types and
hydrogen bond patterns in the overall set, each target selected
SpotXplorer0 hit sets with rings and hydrogen bonds similar to
the distributions of their ChEMBL fragments. This provides
further evidence that a well-designed small fragment library can
contain the majority of the information required for productive
target binding. For the targets studied, fragments containing both
aromatic and non-aromatic rings were preferentially identified as
experimental hits (as represented by the light green rings in
Fig. 3). This is consistent with previously identified preferences
for aromatic character in active fragments9.
Additionally, in the case of Factor Xa and thrombin, the large
number of experimental structures available in the PDB database
allows for an implicit comparison of fragment binding poses.
The possible binding poses of the fragment hits are determined by
the available arrangements of their pharmacophore features, since
these are the structural moieties forming the critical interactions
with the surrounding binding site residues. Therefore, we
performed a comprehensive and comparative analysis of X-ray
validated binding pharmacophores extracted from all available
thrombin and Factor Xa structures, and those pharmacophores
identified by screening the SpotXplorer0 library against these
targets.
Fig. 2 Experimental validation of SpotXplorer0 on known target classes. a SpotXplorer0 pilot library screening yielded a diverse set of confirmed hits for
validated GPCR and protease drug targets. Hits are denoted by color in their respective plate positions (upper panel: 5-HT1A with red, 5-HT6 with green, 5-
HT7 with blue, lower panel: factor Xa with red, thrombin with green). b The handful of hit compounds from SpotXplorer0 represents the majority of
pharmacophore models (black) that occur over the respective sets of (typically 4–11 times more) fragment-sized ligands in the ChEMBL database
(Percentages are reported in Table 1).
Table 1 Summary of fragment hits from the SpotXplorer0









5-HT1A 8 81 80.0 51.5
5-HT6 11 43 100 87.5
5-HT7 4 44 64.3 46.4
Factor Xa 8 1 –b –b
Thrombin 7 76 78.8 54.8
Average – – 80.8 60.0
Retrieval rates of the pharmacophores found in ChEMBL fragments by the SpotXplorer hit
compounds are reported as percentages.
aActive fragments were defined as molecules with 10–16 heavy atoms displaying at least
millimolar activity (expressed as IC50, EC50, Ki, or Kd).
bDue to the small number of active fragments in ChEMBL, retrieval rates were not calculated.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-23443-y
4 NATURE COMMUNICATIONS |         (2021) 12:3201 | https://doi.org/10.1038/s41467-021-23443-y | www.nature.com/naturecommunications
All thrombin and Factor Xa structures were downloaded from
the PDB. Apo structures were eliminated and individual chains
were identified from the holo structures, resulting in 214 and 118
chains for thrombin and Factor Xa, respectively. These chains
were used to identify experimentally validated binding pharma-
cophores according to the same protocol developed for
assembling the non-redundant set of binding pharmacophores
(Supplementary information, section 1.2). Out of the 190 and 97
experimental pharmacophores 124 (65.3%) and 72 (74.2%) of the
thrombin and Factor Xa pharmacophores were included in the
non-redundant set used for designing the SpotXplorer0 library.
Focusing to the 58 pharmacophores defined by the fragment-
sized ligands of thrombin, these were all retrieved by the non-
redundant set.
Next, we crosschecked the individual 2-point and 3-point
pharmacophores appearing in the reported thrombin and Factor
Xa hits from SpotXplorer0 against those that were identified in
the X-ray structures of the respective targets, and found that
86.7% and 85.0% of the X-ray validated pharmacophores were
represented by the SpotXplorer0 hits, respectively. Focusing to
the 58 thrombin-fragment complexes, 90.0% of the X-ray
validated pharmacophores were identified successfully by screen-
ing SpotXplorer0.
Finally, we checked whether the screening hits identified
pharmacophore arrangements that are not available from the
PDB structures. For this analysis we used only thrombin, since
there is only one fragment complex of Factor Xa available.
Considering the 58 thrombin-fragment complexes, there are six
different 2-point and four different 3-point pharmacophores,
while the SpotXplorer0 hits for thrombin represent 26 distinct 2-
point and 43 distinct 3-point pharmacophores. Consequently, our
approach identified 20 and 39 additional 2-point and 3-point
pharmacophores, representing potentially novel poses for the
fragment screening hits.
Fragment hits for challenging and current targets. In addition
to the well-established GPCR and protease targets, the Spot-
Xplorer0 pilot library was screened against more challenging
current targets, including the histone methyltransferase SETD2,
as well as the main protease 3CLPro and the macrodomain NSP3
of the SARS-CoV-2 virus, which is responsible for the ongoing
COVID-19 pandemic.
SETD2 is the only mammalian histone methyltransferase
that can tri-methylate the side chain of K36 on histone H330. Its
role in the progression of acute myeloid leukemia (AML) was
established recently, making it a promising oncotarget14. So far,
only the moderately active natural nucleoside sinefungin and its
derivatives were reported as inhibitors of SETD2 and related
enzymes31. However, they are not cell permeable and lack
selectivity for SETD2. Screening the SpotXplorer0 pilot library
against SETD2 in a chemiluminescence-based enzymatic assay
resulted in two fragments, SX045 and SX084, inhibiting SETD2
function in a dose-dependent manner with IC50 values of
300 and 500 µM, respectively (Supplementary Information,
section 7).
We investigated the effect of the more potent chemotype
(SX045) against SETD2 in a cell-based assay using MOLM-13
and MV4-11 leukemia cells, which were shown before to be
particularly sensitive to SETD2 perturbation14. SX045 exhibited
anti-proliferative effects at an EC50 of 333 and 400 µM in MOLM-
13 and MV4-11 cells, respectively (Fig. 4a). Even though this
fragment was not optimized for cell permeability, this promising
result represents a starting point for further drug development.
We are currently experiencing the COVID-19 pandemic that is
caused by the SARS-CoV-2 virus32. At the time this article is
written, there are over 150 million confirmed cases and over 3
million deaths worldwide33. The scientific community has rapidly
reacted to the unfolding situation, with worldwide collaborative
efforts established at an unprecedented pace. Notably, the
structure of the SARS-CoV-2 main protease 3CLPro, one of the
most promising viral targets, was published in early February
202034. 3CLPro is a viral protease that cleaves the replicated viral
polypeptides into functional proteins35. Viral protease inhibition
is a well-established strategy for the treatment of viral diseases
such as HIV, and HIV protease inhibitors have entered into early
clinical trials against SARS-CoV-236 as well as MERS-CoV37
(although the lopinavir/ritonavir trial against COVID-19 was





























Fig. 3 Topological features of SpotXplorer0 hits vs. ChEMBL fragments. a Selection by pharmacophore results in a relatively even distribution of both
ring types (Ar: only aromatic—light blue, Mix: both aromatic and non-aromatic—light green, No Ar: non-aromatic—yellow) and both atom types (sp2
hybridization—dark red, vs. sp3 hybridization—light red/salmon). b Overall hydrogen bond distribution of ligands in SpotXplorer0 resulting from
pharmacophore matching (HBD: no. of H-bond donors, HBA: no. of H-bond acceptors; 0—dark blue, 1—red, 2—light green, 3—purple, >3—light blue). c
Comparison of SpotXplorer0 hit compounds and ChEMBL fragments for selected targets. Each of the targets shown selects non-overlapping ring subsets:
5-HT1A: mixed ring types with high sp3 character and few hydrogen bond sites; 5-HT6: flatter rings, more aromatic character with moderate hydrogen bond
site counts; Thrombin: non-aromatic sp2 rings with higher hydrogen bond site counts (Colors are identical to panels a and b.).
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SARS-CoV-2 NSP3 is a multidomain protein harboring a
macrodomain module (also referred to as macro X domain) with
enzymatic ADP-ribosyl hydrolase activity39, that has been shown
to suppress human interferon response allowing efficient
replication of the virus in human cells. Therefore, inhibition of
the NSP3 macrodomain has been suggested as a treatment
possibility of coronavirus infections, however, no potent inhibitors
for this enzyme have been discovered to date40.
X-ray crystallography is a very sensitive technique for the
detection of weak binders such as fragments (with affinities in the
high millimolar range), and instantly provides structural
information that can be used to progress the fragments into
potent compounds41,42. With the recent developments at
synchrotrons in high-throughput and automation, it is now
possible to perform an in-crystal fragment screening campaign
within a week. The XChem platform at Diamond Light Source
combines a semi-automatic sample preparation facility with a
fully automated high-throughput beamline. The entire pipeline
involves soaking of the compounds into the crystals43, their
harvesting and unattended data collection. Data analysis and hit
identification are managed within XChemExplorer44, which uses
the Pan Dataset Density Analysis (PanDDA) method for the
identification of weak ligands45. As part of Diamond’s contribu-
tion to the fight against COVID-19, SARS-CoV-2 3CLPro, and
NSP3 macrodomain were screened against SpotXplorer0.
The 3CLPro X-ray screen has resulted in SX013, an aryl-
piperazine fragment located in the active site, in the vicinity of the
catalytic residue C145. The aromatic ring sits at the entrance of
the flexible S2 subsite with the sulfone substituent pointing
towards the S3 subsite and the piperazine moiety located near the
S1′ subsite. The benzene ring provides hydrophobic interactions
with the M49 side chain, while the nitrogen of the piperazine
moiety forms hydrogen bonds with the C44 carbonyl group and
T25 hydroxyl group. The sulfone also interacts with the E166
backbone through hydrogen bonding (Fig. 4b). The location of
this fragment, central to all subsites, suggests it could be further
expanded into S1 and S1′ subsites from the aromatic ring and the
piperazine, while on the other side, the sulfone can be
conveniently used to reach the S3 pocket. The fragment inhibited
3CLPro enzyme activity with an IC50 of 31 µM (Supplementary
Information, section 9)46, and was effective in blocking SARS-
CoV-2 replication in the Vero E6 cell line with an EC50 of
304 µM.
Furthermore, five SpotXplorer0 fragments were identified in
the active site of the NSP3 macrodomain. Comparison of the
fragment-bound structures with the macrodomain structure in
complex with the natural ligand ADP-ribose (PDB ID: 6WOJ)
revealed that three of the fragments (SX003, SX005, and SX054)
bound just above the position (towards the solvent phase), which
is occupied by the adenine moiety of ADP-ribose. All three
fragments also overlay with each other and target the aromatic
sidechain of F156 by (stacked) π–π interactions with their
aromatic bicyclic scaffold. SX005 additionally interacts by
hydrogen bonding with its primary amine with the sidechain of
aspartate D22 and a structural water. The other two identified
fragments, SX048 and SX051, also bind within the adenosine-
binding pocket, however, they overlay in position with the
adenine-proximal ribose of the ADP-ribose. While SX051 seems
to undergo interaction only with its imidazolidine-2,4-dione
moiety by forming a hydrogen bond with the backbone NH of
aspartate D157, SX048 is held nicely in place with two functional
groups being in positions 1 and 4 of the piperidine scaffold. Thus,
SX048 interacts with its primary amide with the V49 backbone
and its carboxyl group allows targeting both backbone NH’s of
F156 and D157 by hydrogen bonding. Furthermore, both
functional groups engage with the water network in the binding
pocket. Significant antiviral activities were detected for SX005,












Fig. 4 Binding poses and cellular activities of SpotXplorer0 hits against challenging and current targets. a Predicted binding pose of the fragment
SX045 (green) in the binding pocket of the SETD2 histone methyltransferase. The fragment decreases the viability of MV4-11 and MOLM-13 leukemia cells
in a dose-dependent manner (see Supplementary Information, section 8), with IC50 values of 400 µM and 333 µM, respectively. b X-ray structure of the
fragment SX013 in complex with the main protease (3CLPro) of the SARS-CoV-2 virus (PDB entry 5RHD). The fragment inhibits the SARS-COV-2-induced
mortality of Vero E6 cells with an EC50 of 304 µM. c X-ray structures of fragments SX005, SX048 and SX051 (left to right) in complex with the NSP3
macrodomain of the SARS-CoV-2 virus (PDB entries 5S4G, 5S4H, and 5S4I). The fragments show antiviral activities with EC50 values in the high
micromolar range in the cellular assay. (In the IC50 and EC50 plots, data are presented as mean values +/− SD, calculated from n= 3 biologically
independent samples.) Source data are provided in the Source Data file.
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(Fig. 4c) with EC50 values as low as 136 µM (for SX051) in our
in vitro infection assay.
Discussion
Fragments have been established as a compact representation of a
much larger chemical space, making the use of fragment libraries
an attractive approach for primary hit discovery47. Pharmaco-
phores are the most generalized representative model for the
spatial layout of physical features required for protein–ligand
binding. This allows for a very good performance-to-cost
ratio48,49, making pharmacophore-based computational screen-
ing a popular method in drug discovery50. To further decrease
computational cost, pharmacophores can be readily implemented
into fingerprint-based approaches51,52. Since this does not place
any constraints on the actual chemical composition, the phar-
macophore concept is especially well-suited for tasks like scaffold
hopping53,54 or library design55.
Compared to earlier approaches, the key difference in our
SpotXplorer library design stems from our realization that the
practical pharmacophore space is unevenly represented. Binding
hotspots are evolutionarily conserved and contribute the majority
of binding free energy for any ligand. The small fraction of
fragments that bind hotspots with a few high-value interactions
are generally privileged while the remainder are rarely active9.
Consequently, instead of systemically generating a combinatorial
pharmacophore ensemble55, we have collected and analyzed the
publicly available set of experimental protein-fragment complexes
in the PDB. A non-redundant set of 425 pharmacophores with a
maximum of four features covers nearly all the described
target–ligand interactions. By optimizing a fragment library to
cover the experimentally verified pharmacophore set in a diverse
way, i.e., where each pharmacophore was represented by a diverse
set of fragments, we aimed to maximize our chances for hit
discovery. This approach could provide viable starting points
against virtually any available protein target.
Recognizing the value of minimal pharmacophores to fragment
binding15, we have produced a 2-point and 3-point pharmaco-
phore optimized library of 96 fragments, the SpotXplorer0 pilot
library. To measure the redundancy present within our selection
(in addition to Fig. 1d), we have performed a principal compo-
nent analysis on the 425 hotspot pharmacophore fingerprints,
without submodels, of SpotXplorer0. We have found that only
45% of the overall data variance can be explained by the first ten
principal components, providing good evidence that the occur-
rences of a given pharmacophore are largely independent from
the occurrences of others. By comparison, in highly correlated
datasets like molecular dynamics simulations of macromolecular
systems or sample classification based on UV/Vis- or infrared
spectra, the first ten principal components often explain almost
100% of the overall variance. Even when the necessarily corre-
lated submodels are included in the dataset, the explained var-
iance of the first ten principal components rises only to 58%.
Additionally, we have compiled key information on the occur-
rence of certain pharmacophoric features (polar, directional,
and apolar features, etc.) in the Supplementary Information,
section 1.6. Notably, there are only 18/6/1% of 2/3/4-pt. phar-
macophores (3% in total) that do not contain any polar features
such as H-bond acceptors/donors or ionic centers. This is in line
with our previous observation that apolar desolvation of frag-
ments alone cannot compensate for rigid-body entropy loss upon
binding5.
In contrast to the conventional ligand-based library design
strategies, SpotXplorer is a protein-based approach that highlights
the importance of explicitly accounting for the experimental
binding pharmacophores in available fragment-protein struc-
tures. SpotXplorer0 shows an excellent coverage of the experi-
mentally validated pharmacophore space (76% and 94% for
unique 2-pt. and 3-pt. pharmacophores, respectively). By com-
parison, a recently published fragment library of the same size
that was compiled by ligand-based methods (ROCS shape and
pharmacophore scores) provides significantly lower coverages
(30% and 49% for unique 2-pt. and 3-pt. pharmacophores,
respectively)56. On the other hand, moving from a ligand-based
to a more protein-based approach might introduce other poten-
tial limitations, such as the correct identification of protonation
states, tautomeric forms and protein-induced polarization effects.
To tackle this challenge, our protocol assigns hydrogen positions
by taking into account relevant pKa values and possible H-bonds,
assigns charges and predicts the most reliable tautomer of the
ligand. This represents a feasible option to consider these effects
as efficiently as possible for the large number of experimental
protein-fragment complexes (close to 4000) used in our study
(Supplementary Information, section 1.2). Also, while the current
set of non-redundant binding pharmacophores is inherently
limited to those that have appeared in at least one publicly
available experimental structure in the PDB, it can be updated to
include newly released structures. Alternatively, the same work-
flow can be utilized to extract a non-redundant set from a dif-
ferent source of experimental structures (such as proprietary in-
house databases).
Experimental screening against several well-established protein
targets has validated our hypothesis, providing a diverse set of
fragment hits for three GPCRs and two proteases (Fig. 2).
Additionally, our approach has successfully yielded fragment hits
for novel, challenging targets such as the histone methyltransfer-
ase SETD2 and two potential drug targets of the SARS-CoV-2
virus, the main protease 3CLPro and the NSP3 macrodomain. In
the latter two cases, X-ray crystallography was employed as the
primary screening format, providing direct feedback and valida-
tion of our pharmacophore-based approach. The experimental
complex of SARS-CoV-2 3CLPro with the fragment SX013
documents PR_0 as the binding pharmacophore, which was















Fig. 5 SpotXplorer0 hits against the SARS-CoV-2 NSP3 macrodomain.
Overlay of the binding poses of the five SpotXplorer0 hits against the
SARS-CoV-2 NSP3 macrodomain (colored sticks, SX003—green, SX005—
light blue, SX048—magenta, SX051—purple, SX054—orange) with the
binding pose of ADP-ribose (gray lines, from PDB structure 6WOJ60).
Three and two hits occupy the adenine and proximal ribose sites,
respectively, providing merging and growing options towards the
neighboring subsites (indicated by black arrows).
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Screening the SpotXplorer0 library against the NSP3 macro-
domain as a novel coronavirus target provided even more proof
of concept. The identified pharmacophores can be classified into
the three clusters DR_0, AN_1 and AAR_0 with different
underlying chemical scaffolds, which engage with several sites of
the ADP-ribose pocket. Importantly, the identified fragments
mimic interactions of the natural ligand ADP-ribose as well as
establish additional interactions with the macrodomain (Fig. 5).
The three fragments of the first cluster (SX003, SX005, and
SX054) are characterized by aromatic bicycles that target the
F156 sidechain—with the H-donor in SX005 additionally tar-
geting the sidechain of D22, which resemble the interactions of
the adenine moiety of ADP-ribose with the macrodomain. With
its primary amide group, SX048 is able to target V49 which
naturally interacts with the phosphate group of the ADP-ribose.
Furthermore, fragment SX048 establishes with its carboxyl group
new interactions with the macrodomain, which are different
compared to ADP-ribose. This hit provides valuable hints of
targetable regions for inhibitor development and presents a
candidate for merging with other fragments that present more
traditional binding poses, especially since its antiviral effect was
already demonstrated in an in vitro infection assay. Moreover,
both SX048 and SX051 provide growing vectors towards the distal
ribose site (with their amide and methyl groups, respectively),
enabling their optimization into highly specific ligands.
Overall, we found that pharmacophore optimized fragments
are mapping the binding sites of protein targets effectively. This
approach was capable of retrieving fragment hits by matching the
known and validated pharmacophores of well-established targets,
thereby providing chemical starting points for novel and chal-
lenging proteins.
Methods
Clustering of experimental structures to non-redundant set of binding phar-
macophores. Fragment-sized ligands of 10–16 heavy atoms15 were filtered to
exclude covalent labels, sugars, buffers, and crystallization additives, and subjected
to large-scale FTMap16,17 analysis to identify fragments bound to hotspots.
Schrödinger’s ePharmacophore protocol was employed to extract pharmacophore
models containing a maximum of four features (A—H-bond acceptor, D—H-bond
donor, H—hydrophobic group, N—negative charge, P—positive charge, R—aro-
matic ring) with the most significant contributions to the overall free energy of
binding, approximated by the Glide XP docking score (without changing the
binding mode)18,19. The observed pharmacophore models were clustered based on
their respective feature sets (level 1, e.g., DRR—an H-bond donor and two aromatic
rings). Then the models of each level 1 cluster were spatially aligned and clustered
based on their root-mean-squared distance (RMSD) values (level 2, e.g., DRR_0,
with 0 being an arbitrarily assigned identifier of the specific 3D layout of the
pharmacophoric features). The workflow resulted in 425 unique level 2 clusters.
For each level 2 cluster, the pharmacophore model that is closest to the cluster
centroid was selected as the cluster representative.
Fragment library optimization. Vendor fragment sets were filtered for size,
rotatable bond count and other properties, and the absence of known problematic
features22. Candidate fragments were annotated with the full 425 non-redundant
set of 2, 3, and 4-point pharmacophore models and stored as fingerprints with bits
for pharmacophores present set to 1. When a molecule fits a 4-point (or 3-point)
model, it trivially fits 2-point and 3-point models with the same geometry (sub-
models). To ensure that these pharmacophore models are represented on their own
rather than only as part of a larger model, a second fingerprint was generated with
bit positions for submodels set to zero (see Fig. 1c, blue circles).
The desired number of molecules was compiled with an algorithm that
iteratively and simultaneously minimized the mean pairwise fingerprint similarity
of the selected molecules (Fig. 1c, green rows), and pharmacophores (Fig. 1c, red
columns), and maximized the number of models represented by at least one
molecule (coverage). For the SpotXplorer0 pilot library, we selected 96 compounds
focusing on the set of 2-point and 3-point pharmacophores with the 2-point
submodels removed. For the last 10% of compounds, acceptable candidate
structures did not significantly alter the overall diversity, so candidates were chosen
to fill missing or underrepresented pharmacophores.
Biochemical screening against the protein targets. GPCR radioligand binding
assays were performed in HEK293 cells with stable expression of human 5-HT1A,
5-HT6, and 5-HT7b receptors (prepared with the use of Lipofectamine 2000). Non-
specific binding was defined with 10 µM of 5-HT in 5-HT1AR and 5-HT7R binding
experiments, whereas 10 µM of mianserin was used in 5-HT6R assays, respectively.
Each compound was tested at 10 µM concentration. Results were expressed as
means of at least two separate experiments. Fragments that exhibited 50% or
stronger inhibition were considered as hits.
Protease inhibitory assays were performed in transparent microtiter plates in a
final volume of 200 µL with the use of chromogenic substrates. The reaction rates
in the absence and in the presence of the inhibitor were measured; screenings were
carried out in duplicate in one independent experiment and Ki values were
determined in triplicate in two independent experiments.
The effect of SX045 on the viability of MOLM-13 and MV4-11 leukemia cells
was evaluated using the CellTiter-Glo Luminescent assay. Cell viability was
determined 5 days after treatment and IC50 values were determined using serial
dilutions starting from 1mM in biological triplicates.
Cellular SARS-COV-2 inhibitory activities were determined in infected Vero E6
cells. Viral copy numbers were determined 48 h post infection, using SARS-CoV-2
RdRp gene specific primers (listed in Supplementary Table 2) and droplet digital
PCR (Bio-Rad Laboratories Inc. QX200 Droplet Digital PCR System).
X-ray screening against SARS-Cov-2 main protease (3CLPro) and NSP3.
Crystals of the 3CLPro and NSP3 macrodomain apo proteins were grown using the
sitting drop vapor diffusion method at 20 °C. NSP3 macrodomain apo crystals were
grown in crystallization drops containing 150 nl of protein solution (47 mg/ml in
20 mM HEPES pH 8.0, 250 mM NaCl, and 2 mM DTT) plus 150 nl crystallization
solution (100 mM CHES pH 9.5 and 30% PEG3000)57. For 3CLPro, crystallization
drops contained 150 nl protein solution (5 mg/ml in 20 mM HEPES pH 7.5 and
50 mM NaCl), 300 nl crystallization solution (11% PEG 4K, 5% DMSO, 0.1 M MES
pH 6.7) and 50 nl seeds58. For both SARS-CoV-2 main protease (3CLPro) and
NSP3 macrodomain, fragments were soaked into crystals by acoustic dispensing43,
adding dissolved compound directly to the crystallization drops using an ECHO
liquid handler (final concentration 10% DMSO); drops were incubated for
approximately 1–3 h prior to mounting and flash freezing in liquid nitrogen.
Data were collected at the beamline I04-1 at 100 K and automatically processed
with Diamond Light Source’s auto-processing pipelines. Most SARS-Cov-2 main
protease (3CLPro) data processed to a resolution of approximately 1.8 Å and NSP3
macrodomain to 1.1 Å. For both targets, data with resolution below 2.8 Å were
excluded. Coordinates, structure factors and PanDDA45 event maps for the
structures discussed are deposited in the Protein Data Bank (PDB IDs 5RHD, 5S4F,
5S4G, 5S4H, 5S4I, and 5S4J). Data collection and refinement statistics are
summarized in the Supplementary Data file, while a more detailed method
description is included in section 9 of the Supplementary Information.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The SpotXplorer0 library is available for screening at Diamond Light Source (https://www.
diamond.ac.uk/Instruments/Mx/Fragment-Screening/Fragment-Libraries0.html). Structure
data that support the findings of this study have been deposited in the PDB database
(https://rcsb.org), with the accession codes 5RHD, 5S4F, 5S4G, 5S4H, 5S4I, and 5S4J. Data
generated during the computational and experimental screening of the described fragment
library are reported in Supplementary Data 1. Structures for assembling the set of non-
redundant pharmacophores were downloaded from the Protein Data Bank (https://www.
rcsb.org/). GPCR and protease ligands and bioactivity data were downloaded from the
ChEMBL database (https://www.ebi.ac.uk/chembl/). Source data are provided with
this paper.
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